
    
      SUMMARY: Alternating Targeted Therapy in Patients with Metastatic Renal Cell Carcinoma: A
      Phase II Study of Alternating Sunitinib and Temsirolimus

      Patients with measurable metastatic renal cell carcinoma (any histology) are eligible. All
      patients will be treated as outlined below with sunitinib alternating with temsirolimus.

      Patients will be treated continuously, until evidence of progression of disease, or for up to
      two cycles following disappearance of all disease.

      A cycle is defined as:

      Sunitinib 50mg by mouth daily for 4 weeks followed by a two week rest Temsirolimus 25mg IV
      weekly for 4 weeks followed by a two week rest
    
  